Projekt
Randomized phase III trial of Herceptin™ followed by Taxol plus Herceptin™ versus the combination of Herceptin™ and Taxol as palliative chemotherapy in patients with HER2-overexpressing advanced breast cancer
Automatisch geschlossen · 1999 bis 2015
Ruhstaller Thomas, Baumann Michael
Art
Klinische Forschung
Reichweite
Multizentrisch, KSSG als teilnehmendes Zentrum
Bereiche
Status
Automatisch geschlossen
Start
1999
Ende
2015
Studiendesign
multicenter, prospective, non-blinded, randomized phase III trial
Schlagwörter (Tags)
Time to progression on combined HerTax,
Projektpartner
Prof. Aron Goldhirsch, Milano
Dr. med. Olivia Pagani, Mendrisio
Kurzbeschreibung/Zielsetzung
To compare efficacy, toxicity and quality of life of the sequential administration of Her alone followed, at PD, by the combination with weekly Tax (Arm A) vs. the upfront combination of both drugs (Arm B) in patients with ABC.